Back to results
US 2021/0060086 A1Published application
Combination therapy for treating or preventing cancer
Assignee4D Pharma Research Limited
InventorAlexander STEVENSON
Life of this patent
Estimating the term…
Abstract
The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.
Claims64
-24. (canceled)
A method of treating cancer in a subject in need thereof, comprising
- administering to said subject (i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:
- 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and (ii) a second pharmaceutical composition that comprises a checkpoint inhibitor, wherein said checkpoint inhibitor is an anti-ganglioside GD3 antibody or a ganglioside GD3 binding fragment thereof,
- whether said first pharmaceutical composition is administered to said subject by oral administration and said second pharmaceutical composition is administered to said subject by parenteral administration, and
- wherein said administering is effective to treat cancer in said subject.
1 more element
A kit for treating cancer in a subject in need thereof, comprising
- (i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:
- 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and
- (ii) a second pharmaceutical composition that comprises a checkpoint inhibitor, wherein said checkpoint inhibitor is an anti-ganglioside GD3 antibody or a ganglioside GD3 binding fragment thereof.
A method of treating cancer in a subject in need thereof, comprising
- administering to said subject (i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:
- 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and (ii) a second pharmaceutical composition that comprises a checkpoint inhibitor selected from the group consisting of:
- Nivolumab, BGB-A317, cemiplimab, PDR001, camrelizumab, BCD-100, IBI308, AGEN2034, INCSHR1210, MEDI0680, JS001/PD1, CC-90006, BI 754091, JNJ-63723283, PF-06801591, GLS-010, AB122, Sym021, MGA012, LZM009, genolimzumab, AK105, and TSR-042,
- whether said first pharmaceutical composition is administered to said subject by oral administration and said second pharmaceutical composition is administered to said subject by parenteral administration, and
- wherein said administering is effective to treat cancer in said subject.
2 more elements
A kit for treating cancer in a subject in need thereof, comprising
- (i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:
- 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and
- (ii) a second pharmaceutical composition that comprises a checkpoint inhibitor selected from the group consisting of:
- Nivolumab, BGB-A317, cemiplimab, PDR001, camrelizumab, BCD-100, IBI308, AGEN2034, INCSHR1210, MEDI0680, JS001/PD1, CC-90006, BI 754091, JNJ-63723283, PF-06801591, GLS-010, AB122, Sym021, MGA012, LZM009, genolimzumab, AK105, and TSR-042.
1 more element
Dependencies are inferred from the claim text.